falsefalse

Optimizing Care in HER2+ Breast Cancer: Integrating Fertility Preservation and Advanced Treatment Approaches - Episode 1

Optimizing Therapy in HR+/HER2+ Breast Cancer: Balancing Endocrine, HER2-Targeted, and Chemotherapy Options

,

Panelists discuss how treatment strategies for triple-positive breast cancer (hormone receptor [HR] positive and HER2 positive) differ from those for hormone receptor–negative, HER2-positive disease, with emphasis on balancing endocrine therapy, HER2-targeted therapy, and chemotherapy.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    Treatment Strategies for Triple-Positive Breast Cancer

    Panel Introduction

    Moderators and Panelists:

    • Dr Kelly McCann, MD, PhD - Breast medical oncologist and assistant professor at the David Geffen School of Medicine at UCLA
    • Dr Gregory Vidal, MD, PhD - Breast medical oncologist at West Cancer Center and Research Institute; associate professor at the University of Tennessee Health Sciences Center; director of clinical research at West Cancer Center

    Key Themes:

    • Triple-positive breast cancer characteristics
      • Defined as HR-positive and HER2-positive breast cancer
      • Shows different prognosis and treatment response compared with HR-negative, HER2-positive disease
      • According to SEER database, has better prognosis than HR-negative, HER2-positive breast cancer
      • About half exhibit luminal A or B phenotype (Kim et al, 2019)
    • Standard treatment approaches
      • Standard of care includes taxane with pertuzumab and trastuzumab
      • Chemotherapy eventually discontinued with antiestrogen therapy added to the backbone
      • PATINA study showed adding cyclin-dependent kinase (CDK) 4/6 inhibitor to antiestrogen therapy resulted in progression-free survival benefit
    • CDK 4/6 inhibitors and triplet therapy
      • monarcHER trial demonstrated better outcomes with CDK 4/6 inhibitor plus antiestrogen therapy and trastuzumab compared with chemotherapy and trastuzumab
      • PATINA trial showed adding palbociclib to maintenance therapy improved progression-free survival (44.3 months vs 29.1 months)
      • Toxicity considerations include neutropenia, gastrointestinal adverse effects, fatigue, menopausal symptoms, and cardiac monitoring requirements

    Notable Insights:

    • Dr Vidal noted: “Standard of care in this setting is really a taxane with pertuzumab and trastuzumab with chemotherapy eventually dropping off, and with the addition of antiestrogen therapy to that backbone.”
    • Dr McCann emphasized: “I think it’s very important to remember that even though we think of triple-positive cancers as predominantly HER2 driven, that’s not necessarily true. There’s actually a lot of crosstalk between HER2 and the estrogen receptor pathways in terms of growth signals.”
    x